Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinchun Yan

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
American Journal of Clinical Oncology|February 13, 2014
Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional ExperienceJinchun Yan, Qin Liu, Jessica N Moseley, et al.
Oncotarget|July 11, 2015
AKAP4 is a circulating biomarker for non-small cell lung cancerKiranmai Gumireddy, Anping Li, David H Chang, et al.
Chinese Medical Journal|July 23, 2023
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Jianzhong Zhang, Bin Yang, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
American Journal of Clinical Oncology|February 13, 2014
Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional ExperienceJinchun Yan, Qin Liu, Jessica N Moseley, et al.
Oncotarget|July 11, 2015
AKAP4 is a circulating biomarker for non-small cell lung cancerKiranmai Gumireddy, Anping Li, David H Chang, et al.
Chinese Medical Journal|July 23, 2023
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Jianzhong Zhang, Bin Yang, et al.
The Lancet. Oncology|January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialLuis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 3